Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569491 · ClinicalTrials.gov registry record · Phase 4
TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program
A Phase 4 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,585
- Enrollment target
NCT00569491 is a Phase 4 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 2,585 participants.
The verdict
NCT00569491, a Phase 4 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,585 participants
- Enrollment target
Study Summary
The TAXUS ARRIVE study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Interventions
- DEVICE TAXUS Express 2™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,585 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569491
The ClinicalTrials.gov registry entry for NCT00569491 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,585 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAXUS Express 2™ is the first listed.
NCT00569491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569491 about?
NCT00569491 is a clinical study titled "TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program". The TAXUS ARRIVE study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
What is the current status of trial NCT00569491?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,585 participants. The study started on 2004-02. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00569491?
The interventions under investigation include: TAXUS Express 2™ (DEVICE).
Who is sponsoring clinical trial NCT00569491?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.